The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing
Open Access
- 1 January 2015
- journal article
- research article
- Published by Hindawi Limited in Canadian Journal of Gastroenterology and Hepatology
- Vol. 29 (1) , 46-48
Abstract
Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per antiviral regimen is increasing, the cost per cure is decreasing, especially with interferon-free therapy. In a publicly funded health care system, the lowest cost per cure is a more valuable measure of value for public money than the cost per regimen.Keywords
This publication has 15 references indexed in Scilit:
- Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGETJournal of Hepatology, 2015
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological responseHepatology, 2014
- Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trialsJournal of Hepatology, 2014
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosingJournal of Hepatology, 2010
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001